Tetraethylene Glycol

Tetraethylene Glycol

SCHEMBL2541664

C=C.C=C.C=C.OCCOCCOCCOCCO

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.85
KMT2A Q03164 4/20 0.85
TSHR P16473 5/20 0.77
MAPK1 P28482 2/20 0.77
ALDH1A1 P00352 4/20 0.50
THRB P10828 1/20 0.50
HTT P42858 1/20 0.50
MAPT P10636 1/20 0.50
APP P05067 5/20 0.34
TP53 P04637 2/20 0.33
HIF1A Q16665 2/20 0.33
HSD17B10 Q99714 1/20 0.33
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31
CYP3A4 P08684 1/20 0.31
CASP1 P29466 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
SLCO1B3 Q9NPD5 1/20 0.31
SLCO1B1 Q9Y6L6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triethylene Glycol SCHEMBL421335 1.00 MEN1 (0.85) MEN1KMT2ATSHRMAPK1ALDH1A1
Hexaethylene Glycol SCHEMBL9719640 1.00 MEN1 (0.85) MEN1KMT2ATSHRMAPK1ALDH1A1
Triethylene Glycol SCHEMBL21384854 1.00 MEN1 (0.85) MEN1KMT2ATSHRMAPK1ALDH1A1
Triethylene Glycol SCHEMBL4603067 1.00 MEN1 (0.85) MEN1KMT2ATSHRMAPK1ALDH1A1
Triethylene Glycol SCHEMBL16394863 0.96 MEN1 (0.79) MEN1KMT2ATSHRMAPK1ALDH1A1
Triethylene Glycol SCHEMBL6249482 0.96 MEN1 (0.79) MEN1KMT2ATSHRMAPK1ALDH1A1
Triethylene Glycol SCHEMBL444830 0.96 MEN1 (0.79) MEN1KMT2ATSHRMAPK1ALDH1A1
Di(Hydroxyethyl)Ether SCHEMBL8330422 0.96 TSHR (0.83) MEN1KMT2ATSHRMAPK1ALDH1A1
Di(Hydroxyethyl)Ether SCHEMBL8581564 0.96 TSHR (0.83) MEN1KMT2ATSHRMAPK1ALDH1A1
Di(Hydroxyethyl)Ether SCHEMBL486990 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11577454-B2 Three-dimensional printing HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2023-02-14 US claimed
US-11331358-B2 Pharmaceutical composition and method of manufacturing SINDERBRAND LAW GROUP, PC 2022-05-17 US disclosed
US-20200246406-A1 PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING CURE PHARMACEUTICAL HOLDING CORP. (US) 2020-08-06 US disclosed
US-10624940-B2 Pharmaceutical composition and method of manufacturing CURE PHARMACEUTICAL HOLDING CORP. (US) 2020-04-21 US disclosed
US-20190209633-A1 PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING SINDERBRAND LAW GROUP, PC 2019-07-11 US disclosed
US-10125155-B2 Silane modified formamides COVESTRO DEUTSCHLAND AG (DE) 2018-11-13 US disclosed
US-20180034055-A1 COMPOSITE INCLUDING POROUS GRAPHENE AND CARBON NANOTUBE MATERIAL University-Industry Foundation, Yonsei University (KR) 2018-02-01 US disclosed
US-20160340371-A1 SILANE MODIFIED FORMAMIDES COVESTRO DEUTSCHLAND AG (DE) 2016-11-24 US disclosed
US-20160280977-A1 Two-Part Urethane Adhesive IFS Industries Inc. 2016-09-29 US disclosed
US-9221984-B2 Cross-linked pigment dispersion based on polyurethane dispersants E I DU PONT DE NEMOURS AND COMPANY (US) 2015-12-29 US disclosed
US-20130102729-A1 CROSS-LINKED PIGMENT DISPERSION BASED ON POLYURETHANE DISPERSANTS E I DU PONT DE NEMOURS AND COMPANY (US) 2013-04-25 US disclosed
US-8361264-B2 Process for producing polarizing plate, polarizing plate produced by the process, and liquid crystal display device using the polarizing plate KONICA MINOLTA OPTO, INC. (JP) 2013-01-29 US disclosed
US-20110308712-A1 PROCESS FOR PRODUCING POLARIZING PLATE, POLARIZING PLATE PRODUCED BY THE PROCESS, AND LIQUID CRYSTAL DISPLAY DEVICE USING THE POLARIZING PLATE KONICA MINOLTA OPTO, INC. (JP) 2011-12-22 US disclosed
US-20110263741-A1 SOFT POLYURETHANE FOAM WITH LOW RESILIENCE AND THE PREPARATION METHOD THEREOF U CLEAN ASIA LIMITED (CN) 2011-10-27 US disclosed
US-20100221457-A1 OPTICAL COMPENSATION FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY EMPLOYING THE SAME KONICA MINOLTA OPTO, INC. (JP) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125155-B2 Silane modified formamides PFAS, ITGA8, NBAS MEN1 752/4885KMT2A 119/4885TSHR 4873/4885
US-20200246406-A1 PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING CNR2, CNR1, CYP3A5 MEN1 3386/4885KMT2A 2610/4885TSHR 4585/4885
US-11331358-B2 Pharmaceutical composition and method of manufacturing CNR2, CNR1, CYP3A5 MEN1 3386/4885KMT2A 2610/4885TSHR 4585/4885
US-20160340371-A1 SILANE MODIFIED FORMAMIDES PFAS, ITGA8, NBAS MEN1 695/4885KMT2A 118/4885TSHR 4870/4885
US-20190209633-A1 PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING CNR2, CNR1, CYP3A5 MEN1 3386/4885KMT2A 2610/4885TSHR 4585/4885
US-10624940-B2 Pharmaceutical composition and method of manufacturing CNR2, CNR1, CYP3A5 MEN1 3386/4885KMT2A 2610/4885TSHR 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.